Thomas Guldager Lauridsen

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9

No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial

Ditte Hansen, Knud Rasmussen, H. Danielsen et al. · Kidney International · 2011 · 85 citations

Hemodialysis, Urology, Secondary Hyperparathyroidism +11

Effect of potassium supplementation on renal tubular function, ambulatory blood pressure and pulse wave velocity in healthy humans

Solveig Klok Matthesen, Thomas Larsen, Henrik Vase et al. · Scandinavian Journal of Clinical and Laboratory Investigation · 2011 · 49 citations

Hypertension, Crossover Trial, Nephrology +20

Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study

E. B. Pedersen, I.M. Thomsen, Thomas Guldager Lauridsen · BMC Nephrology · 2010 · 33 citations · Full text

Increased renal sodium absorption by inhibition of prostaglandin synthesis during fasting in healthy man. A possible role of the epithelial sodium channels

Thomas Guldager Lauridsen, Henrik Vase, Jørn Starklint et al. · BMC Nephrology · 2010 · 27 citations · Full text